Jun 11 2012
Today CLC bio announced the completion and final implementation of a
specialized antibody engineering and selection module for Crucell, one
of the Janssen Pharmaceutical Companies of Johnson & Johnson, that
integrates with CLC bio's bioinformatics platform. The specialized
module is designed to optimize the end-to-end workflow and analysis
pipeline when working with a large number of antibodies during the
process of developing new therapies for various diseases amongst which
infectious diseases and cancer
"When investigating the diversity and complexity of antibody
repertories, speed and quality are essential. The faster we can go
through our bioinformatics workflow and identify antibodies of interest,
the earlier we can move to the next phases in our research and
development, which is of course extremely important for us" says
Innovation & Discovery Scientist at Crucell, David Zuijdgeest, and
continues, "CLC bio has fully integrated the workflow by
automating all the steps in the downstream bioinformatics analysis
process. Not only has this accelerated the research process tremendously
by eliminating tedious and complicated manual procedures, but it also
provides a high quality and robust workflow."
Director of Consulting Services at CLC bio, Dr. Jannick D. Bendtsen,
continues, "This intricate solution which we have customized for
Crucell stresses the flexibility and stability of our bioinformatics
platform. And apart from a commercial point of view, it's also a
personal pleasure for us to assist Crucell in discovering and developing
products that combat infectious diseases, which ultimately helps saving
lives and preventing illness around the world."
Source: CLC bio